Connect to other sites within the UBM Medica Network
Update on the Management of Myeloproliferative Neoplasms
In this interview we discuss symptoms and prognosis for patients with polycythemia vera and essential thrombocythemia and the treatment of myelofibrosis.
Prostate Biopsy From 56-Year-Old Patient
A prostate biopsy is obtained from a 56-year-old man. What is your diagnosis?
Role for Ibrutinib Confirmed in Relapsed/Refractory 17p Deletion CLL
Phase II data provide further evidence that patients with relapsed/refractory chronic lymphocytic leukemia with 17p deletion have a new treatment option with ibrutinib.
Benefits of Colon Cancer Screening Decrease After Age 75
Colonoscopy screening is modestly effective for preventing colorectal cancer in patients aged 70 to 74, but the benefits may begin to diminish after that.
I-131 for Thyroid Cancer Metastases
In this interview we discuss which distant metastases in thyroid cancer are appropriate targets for I-131 treatment, appropriate dosing, and more.
FDA Announces Nivolumab Dose Change for RCC, NSCLC, Metastatic Melanoma
The FDA announced a modification to the recommended dosage regimen for nivolumab (Opdivo) for renal cell carcinoma (RCC), metastatic melanoma, and non–small-cell lung cancer (NSCLC).
Higher RT Dose in Pediatric Brain Tumors Limited Vocabulary Development
In children with primary brain tumors who were treated with cranial radiation, cerebral volume and radiation dose may affect the rate of vocabulary development.
Patient Presents With Tumor in the Epididymis
A 38-year-old man presents with a tumor in the epididymis, and a biopsy is performed. What is your diagnosis?
Realities of Phase I Clinical Trials May Not Match Patient Expectations
More than 80% of patients referred for consideration in a phase I clinical trial were still willing to participate after a consultation where they learned more about trial participation.
PI3K, HDAC Inhibition With CUDC-907 Shows Promise in Thyroid Cancer
Dual inhibition of PI3K signaling and histone deacetylase 2 (HDAC2) enzymes with CUDC-907 slowed thyroid tumor cell proliferation, tumor progression and metastasis, according to a preclinical study.
By clicking Accept, you agree to become a member of the UBM Medica Community.